Phosphoinositide 3-Kinase Function in Lymphocytes
Phosphoinositide 3-Kinase Function in Lymphocytes
批准号:
6837137
负责人:
DAVID Alexander FRUMAN
金额:
$34.29万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-01-01 至 2006-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-range goal of this project is to
define the mechanism of phosphoinositide 3-kinase (PI3K) signaling in
lymphocytes. As PI3K is required for lymphocyte proliferation, advances in this
area may lead to novel strategies for the treatment of immunodeficiency,
autoimmunity, transplant rejection and cancer. The central hypothesis guiding
this application is that the PI3K regulatory isoforms p85alpha and p85beta have
distinct functional roles in lymphocyte signaling. To test this hypothesis,
this investigator?s laboratory has generated mice lacking either p85alpha or
p85beta. p85alpha-deficient mice exhibit B cell defects similar to those seen
in mice lacking Btk, BLNK or PLCgamma2. These findings support a model that
PI3K activation is important for membrane assembly of a signaling complex that
facilitates PLCgamma2 activation and sustained calcium flux. T cells and B
cells rely on distinct proteins to carry out many of the signaling steps that
link the antigen receptor to calcium flux and proliferation. For example,
calcium flux in T cells is regulated by Itk, a functional homolog of Btk.
Preliminary results suggest that p85beta may be an important PI3K regulatory
isoform in T cell signaling. This application has three specific aims: Aim 1 is
to test the model that p85alpha is required for activation of Btk and PLCgamma2
leading to sustained Ca2+ flux. Biochemical assays will be used to analyze
signaling in primary B cells and immortalized B cell lines lacking p85alpha.
Aim 2 is determine if p85beta is required for T cell proliferation and cytokine
production. Aim 3 is to determine whether p85beta is required for activation of
Itk, PLCgamma1, and sustained Ca2+ flux in T cells. Biochemical assays will be
used to analyze signaling in purified T cells. These studies will increase our
understanding of PI3K signaling, a central control point in lymphocyte
proliferation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer
-
批准号:9178942
-
项目类别:
-
资助金额:$17.85万
-
财政年份:2016
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer
-
批准号:9316613
-
项目类别:
-
资助金额:$19.77万
-
财政年份:2016
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Regulation of B cell differentiation by eIF4E
-
批准号:9244731
-
项目类别:
-
资助金额:$18.37万
-
财政年份:2016
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Combination strategies to enhance therapy for Ph-like B-ALL
-
批准号:8912208
-
项目类别:
-
资助金额:$25.67万
-
财政年份:2015
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
UCI-GPS: UC Irvine Graduate Professional Success
-
批准号:9341983
-
项目类别:
-
资助金额:$31.79万
-
财政年份:2014
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
UCI-GPS: UC Irvine Graduate Professional Success
-
批准号:8929336
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2014
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
UCI-GPS: UC Irvine Graduate Professional Success
-
批准号:8829529
-
项目类别:
-
资助金额:$34.02万
-
财政年份:2014
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Solving the elusive mechanism of rapamycin action in lymphocytes
-
批准号:8285697
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8628792
-
项目类别:
-
资助金额:$30.18万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Solving the elusive mechanism of rapamycin action in lymphocytes
-
批准号:8531852
-
项目类别:
-
资助金额:$21.72万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8815271
-
项目类别:
-
资助金额:$31.03万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8238745
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
-
批准号:8442848
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2012
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Immunoregulatory effects of novel mTOR inhibitors
-
批准号:7774553
-
项目类别:
-
资助金额:$7.2万
-
财政年份:2010
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Immunoregulatory effects of novel mTOR inhibitors
-
批准号:8019056
-
项目类别:
-
资助金额:$7.12万
-
财政年份:2010
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
LIVE CELL IMAGING OF CD4+ T-CELL CHEMOKINESIS OVER IMMOBILIZED CCL21
-
批准号:7724055
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2008
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
PI3K Signaling in Single Lymphocytes Analyzed by LMS
-
批准号:6710897
-
项目类别:
-
资助金额:$18.54万
-
财政年份:2004
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
PI3K Signaling in Single Lymphocytes Analyzed by LMS
-
批准号:6878064
-
项目类别:
-
资助金额:$22.4万
-
财政年份:2004
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Phosphoinositide 3-Kinase Function in Lymphocytes
-
批准号:6620748
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2002
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
Phosphoinositide 3-Kinase Function in Lymphocytes
-
批准号:6609015
-
项目类别:
-
资助金额:$2.23万
-
财政年份:2002
-
负责人:DAVID Alexander FRUMAN
-
依托单位:
海外基金